Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.07 Insider Own0.60% Shs Outstand145.83M Perf Week11.08%
Market Cap7.23B Forward P/E87.04 EPS next Y0.57 Insider Trans3.55% Shs Float144.91M Perf Month15.72%
Income-10.30M PEG- EPS next Q0.02 Inst Own97.20% Short Float2.91% Perf Quarter16.02%
Sales577.90M P/S12.52 EPS this Y-33.30% Inst Trans-0.11% Short Ratio4.71 Perf Half Y4.29%
Book/sh9.33 P/B5.32 EPS next Y112.69% ROA-0.60% Target Price50.92 Perf Year36.33%
Cash/sh4.38 P/C11.33 EPS next 5Y28.80% ROE-0.90% 52W Range34.28 - 54.25 Perf YTD22.01%
Dividend- P/FCF125.17 EPS past 5Y-38.50% ROI1.90% 52W High-5.47% Beta1.13
Dividend %- Quick Ratio8.10 Sales past 5Y5.80% Gross Margin70.50% 52W Low49.59% ATR1.77
Employees1250 Current Ratio8.70 Sales Q/Q10.70% Oper. Margin-6.40% RSI (14)76.83 Volatility3.76% 4.01%
OptionableYes Debt/Eq0.27 EPS Q/Q-60.00% Profit Margin-1.80% Rel Volume1.04 Prev Close49.61
ShortableYes LT Debt/Eq0.26 EarningsOct 29 BMO Payout- Avg Volume896.60K Price51.28
Recom2.40 SMA2018.47% SMA5017.19% SMA20011.51% Volume736,413 Change3.37%
31-Jul-14Reiterated Mizuho Buy $61 → $59
10-Apr-14Upgrade Mizuho Neutral → Buy $55 → $61
09-Apr-14Reiterated MKM Partners Sell $32 → $35
28-Feb-14Reiterated UBS Neutral $42 → $53
28-Feb-14Reiterated MKM Partners Sell $26 → $32
28-Feb-14Reiterated Mizuho Neutral $33 → $56
05-Dec-13Downgrade UBS Buy → Neutral $37 → $42
01-Nov-13Reiterated Mizuho Neutral $30 → $33
30-Oct-13Initiated FBR Capital Mkt Perform $31
24-May-13Reiterated UBS Buy $32 → $37
24-May-13Downgrade MKM Partners Neutral → Sell
18-Apr-13Downgrade Mizuho Buy → Neutral $30 → $26
17-Apr-13Reiterated MKM Partners Neutral $23 → $25
23-Jan-13Downgrade MKM Partners Buy → Neutral
16-Nov-12Initiated Mizuho Buy $27
25-Jan-12Upgrade MKM Partners Neutral → Buy $19 → $20
23-Aug-11Upgrade UBS Neutral → Buy $20.50 → $21
08-Jul-11Reiterated UBS Neutral $19 → $20.50
07-Jun-11Reiterated UBS Neutral $16.50 → $19
10-May-11Reiterated UBS Neutral $14.50 → $16.50
29-Oct-14 10:07AM  Alkermes reports 3Q loss AP
08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today CCBN
07:11AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:07AM  Q3 2014 Alkermes Plc Earnings Release - Before Market Open CCBN
07:00AM  Alkermes plc Reports Third Quarter 2014 Financial Results Business Wire
22-Oct-14 04:00PM  Alkermes to Host Conference Call to Discuss Third Quarter 2014 Financial Results Business Wire
07:00AM  Alkermes New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA Business Wire
24-Sep-14 06:15PM  Cramer's favorite large cap biotech plays CNBC
09:45AM  ALKERMES PLC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
16-Sep-14 06:00AM  'Mad Money' Lightning Round: Buy, Buy, Buy St Jude Medical at TheStreet
04-Sep-14 05:10PM  Alkermes Completes Enrolment for Phase II ALKS 3831 Study Zacks
03-Sep-14 05:14PM  Massachusetts jail offers $1,000-a-shot drug to fight addiction, recidivism Reuters
10:45AM  Credit Suisses 4 Top Pharmaceutical Stocks to Buy for the Rest of 2014 24/7 Wall St.
07:00AM  Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic Business Wire
02-Sep-14 04:00PM  Alkermes Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Business Wire
27-Aug-14 06:10PM  Alkermes Begins a Study on ALKS7106 for Treatment of Pain Zacks
26-Aug-14 06:00PM  Alkermes Gains on Aripiprazole Lauroxil NDA Submission Zacks
07:00AM  Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 7106 for Treatment of Pain Business Wire
25-Aug-14 07:00AM  Alkermes Submits New Drug Application to FDA for Aripiprazole Lauroxil for Treatment of Schizophrenia Business Wire
08-Aug-14 10:25AM  Wall Street Transcript Interview with Howard Zauberman, the President and CEO of Vision-Sciences, Inc. (VSCI) Wall Street Transcript
04-Aug-14 02:40PM  Alkermes Reports Loss in Q2 on Higher Costs, Revenues Up Zacks
31-Jul-14 08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today CCBN -7.69%
07:07AM  Q2 2014 Alkermes plc Earnings Release - Before Market Open CCBN
07:05AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:00AM  Alkermes plc Reports Second Quarter 2014 Financial Results Business Wire
30-Jul-14 07:00AM  Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major Depressive Disorder Business Wire
24-Jul-14 04:00PM  Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results Business Wire
23-Jul-14 07:10AM  Is Alkermes plc Stock Undervalued? at Motley Fool
21-Jul-14 03:40PM  Alkermes' Pipeline Development Impresses, Key Updates Ahead Zacks
17-Jul-14 07:05AM  Alkermes announces initiation of Phase 1 study of ALKS 8700 for treatment of MS at theflyonthewall.com
07:00AM  Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis Business Wire
09-Jul-14 07:00AM  Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates Business Wire
08-Jul-14 12:47PM  Momentum names slammed as volatility comes back at CNBC
09:55AM  Why Mylan Should Buy Alkermes at Motley Fool
23-Jun-14 07:04AM  Alkermes plc (ALKS) Jumps: Stock Rises 5.7% Zacks
20-Jun-14 07:00AM  Lundbeck Delivers Some Data-Driven Upside at Seeking Alpha +5.71%
19-Jun-14 10:40AM  Alkermes' Aripiprazole Lauroxil Looks Promising Zacks
18-Jun-14 08:17AM  New Alkermes Schizophrenia Drug -- An Important Advance With Social Benefits at Forbes
07:03AM  Alkermes presents aripiprazole lauroxil phase 3 data theflyonthewall.com
07:00AM  Alkermes Presents Phase 3 Data From Successful Pivotal Study of Aripiprazole Lauroxil for Treatment of Schizophrenia at ASCP Annual Meeting Business Wire
11-Jun-14 04:00PM  Alkermes Progresses with its Late Stage Candidate Zacks
10-Jun-14 07:05AM  Alkermes announces initiation of FORWARD-3, FORWARD-4 efficacy studies at theflyonthewall.com
07:00AM  Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for ALKS 5461 for Treatment of Major Depressive Disorder Business Wire
09-Jun-14 02:27PM  What's in a Name? Alkermes Thinks Alkeus is too Close for Comfort at The Wall Street Journal
06-Jun-14 03:30PM  Alkermes' Pipeline Holds Promise Zacks
05-Jun-14 12:00AM  Sanofi, Alkermes Name, Pandora: Intellectual Property at Bloomberg
03-Jun-14 07:00AM  Alkermes to Present Data on New Medicines in Development for Schizophrenia and Depression at Upcoming American Society of Clinical Psychopharmacology Annual Meeting Business Wire
02-Jun-14 07:00AM  Alkermes Announces Initiation of Second Phase 2 Clinical Study of ALKS 3831, a Novel Broad-Spectrum Oral Antipsychotic Business Wire
31-May-14 12:47AM  [$$] Ivy Mid Cap Growth: Rethinking Risk at Barrons.com
28-May-14 04:53PM  ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secur EDGAR Online
27-May-14 04:00PM  Alkermes Corporate Presentation to be Webcast at Two Upcoming Conferences Business Wire
16-May-14 08:50AM  Top Analyst Upgrades and Downgrades: J.C. Penney, Micron, Twitter, NBG, SanDisk and More at 24/7 Wall St.
05:38AM  Alkermes assumed with a Buy at Jefferies at theflyonthewall.com
14-May-14 07:16AM  Leerink to hold a bus tour at theflyonthewall.com
12-May-14 04:00PM  Alkermes Corporate Presentation to be Webcast at the UBS Global Healthcare Conference Business Wire
01-May-14 10:50AM  Wider-than-expected Loss at Alkermes, Revenues Slip Zacks
30-Apr-14 03:08PM  Alkermes' CEO Discusses Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
08:30AM  Alkermes plc Earnings Call scheduled for 8:30 am ET today CCBN
08:25AM  Alkermes plc Discusses Q4 2014 Results (Webcast) at Seeking Alpha
07:13AM  Alkermes says 'on track" to submit aripiprazole lauroxil NDA in Q3 theflyonthewall.com
07:07AM  Q1 2014 Alkermes plc Earnings Release - Before Market Open CCBN
07:06AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:00AM  Alkermes plc Reports First Quarter 2014 Financial Results Business Wire
23-Apr-14 04:00PM  Alkermes to Host Conference Call to Discuss First Quarter 2014 Financial Results Business Wire
17-Apr-14 08:31PM  Xenoport's Path Is Long, But The Potential Is There at Seeking Alpha
16-Apr-14 06:30PM  The Biggest Biotech Wins of the Week at Motley Fool +5.14%
09:07AM  Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data Zacks
11-Apr-14 06:41AM  Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% Zacks
10-Apr-14 03:39PM  Gilead Announces Encouraging Sovaldi Data Zacks
08:21AM  [video] Alkermes is a true drug innovator: CEO at CNBC
05:57AM  Alkermes upgraded by Mizuho Briefing.com
09-Apr-14 06:45PM  Lightning Round: Citigroup, Disney & More at CNBC +7.53%
05:30PM  Oncolytics Reports Additional Data on Reolysin Zacks
11:48AM  Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns Zacks
10:50AM  Positive Trial Data Lifts Alkermes Zacks
08-Apr-14 03:33PM  Alkermes to seek schizophrenia drug approval after trial success Reuters
01:06PM  Why Alkermes PLC Shares Temporarily Spiked Higher at Motley Fool
12:57PM  Alkermes Scores Phase 3 Win for Long-Lasting Schizophrenia Drug at Motley Fool
12:12PM  Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3 at Investor's Business Daily
11:51AM  [$$] Alkermes Treatment for Schizophrenia Shows Positive Results at The Wall Street Journal
11:10AM  Halozyme Falls on Phase II Study Halt Zacks
10:53AM  UPDATE 1-Alkermes' schizophrenia drug meets main goal of late-stage study Reuters
10:40AM  Bristol-Myers Seeks FDA Approval for HCV Candidates Zacks
09:26AM  RadNet Touches New 52-Week High Zacks
09:24AM  Ahead of the Bell: Alkermes shares jump AP
09:11AM  Alkermes Will Seek U.S. Approval for Once-Monthly Schizophrenia Treatment at TheStreet
08:00AM  The Boston Beer Company Earnings Call scheduled for 8:00 am ET today CCBN
07:10AM  Alkermes' schizophrenia drug meets main goal of late-stage study Reuters
Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to severe pain; EMEND to treat nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES to treat cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE to prevent renal transplant rejection; NAPRELAN for mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFEDlTAB CR for hypertension; DILZEM SR, DILZEM XL, DILTELAN, and CARDIZEM CD for hypertension and/or angina; and ZOHYDRO ER for severe pain. In addition, it is developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 33, which has completed Phase II study for modulation of brain opioid receptors; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a phase II study medicine to treat schizophrenia; ALKS 8700, a prodrug of monomethyl fumarate to treat multiple sclerosis; ALKS 7106, a small-molecule product candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary biologic cancer immunotherapy candidate. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Oct 23Option Exercise16.5514,577241,24947,104Oct 23 05:17 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Oct 23Sale45.0014,577655,96532,527Oct 23 05:17 PM
POPS RICHARD FDirector and CEO, Alkermes plcOct 16Option Exercise14.9050,000745,000570,063Oct 16 05:30 PM
POPS RICHARD FDirector and CEO, Alkermes plcOct 16Sale41.1850,0002,058,912520,063Oct 16 05:30 PM
POPS RICHARD FDirector and CEO, Alkermes plcOct 15Option Exercise14.9050,000745,000570,063Oct 16 05:30 PM
POPS RICHARD FDirector and CEO, Alkermes plcOct 15Sale41.0650,0002,053,110520,063Oct 16 05:30 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Oct 14Option Exercise14.9015,000223,500145,521Oct 16 05:26 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Oct 14Sale40.6515,000609,737130,521Oct 16 05:26 PM
FRATES JAMES MSVP & CFO, Alkermes plcOct 08Option Exercise11.7316,000187,60060,225Oct 10 05:20 PM
FRATES JAMES MSVP & CFO, Alkermes plcOct 08Sale41.0016,000656,07744,225Oct 10 05:20 PM
Cooke ShanePresident, Alkermes plcOct 05Option Exercise0.0012,500039,160Oct 06 05:35 PM
BREYER ROBERT ADirectorOct 01Option Exercise18.295,00091,45058,156Oct 03 05:06 PM
BREYER ROBERT ADirectorOct 01Sale42.595,000212,95053,156Oct 03 05:06 PM
FRATES JAMES MSVP & CFO, Alkermes plcSep 24Option Exercise11.7316,000187,60060,225Sep 24 05:25 PM
FRATES JAMES MSVP & CFO, Alkermes plcSep 24Sale45.2916,000724,64044,225Sep 24 05:25 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Sep 18Option Exercise14.9015,000223,500145,521Sep 19 05:23 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Sep 18Sale45.6015,000684,063130,521Sep 19 05:23 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 17Option Exercise14.9050,000745,000570,063Sep 19 05:19 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Sep 17Option Exercise15.9114,900237,08647,427Sep 19 05:21 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Sep 17Sale45.0414,900671,04732,527Sep 19 05:21 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 17Sale44.8950,0002,244,585520,063Sep 19 05:19 PM
FRATES JAMES MSVP & CFO, Alkermes plcSep 10Option Exercise11.7316,000187,60060,225Sep 12 05:05 PM
FRATES JAMES MSVP & CFO, Alkermes plcSep 10Sale43.1816,000690,82644,225Sep 12 05:05 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Sep 02Option Exercise11.741,10012,91433,627Sep 04 05:25 PM
MITCHELL PAUL JDirectorSep 02Option Exercise11.841,00011,8409,000Sep 02 05:07 PM
BREYER ROBERT ADirectorSep 02Option Exercise18.295,00091,45058,156Sep 02 05:10 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Sep 02Sale45.081,10049,59232,527Sep 04 05:25 PM
BREYER ROBERT ADirectorSep 02Sale45.125,000225,60053,156Sep 02 05:10 PM
MITCHELL PAUL JDirectorSep 02Sale45.121,00045,1208,000Sep 02 05:07 PM
BLOOM FLOYD EDirectorAug 28Option Exercise16.7720,000335,400110,281Sep 02 05:06 PM